HANALL PHARMA ACQUIRES RIGHTS FOR THREE PROTEIN DRUGS

Nautilus Biotech announced it has signed a collaboration and license agreement with HanAll Pharmaceutical, based in South Korea, to develop and commercialize three of Nautilus' products: Belerofon, Vitatropin and Eporal.

Under the terms of the agreement, HanAll will develop, manufacture and market the licensed products in South Korea. Nautilus will receive an upfront payment, milestone payments associated with development and royalty payments based on net sales of products in South Korea.

Belerofon (Interferon alpha) could treat a number of conditions, including chronic hepatitis C infection, according to Nautilus, and Vitatropin, a human growth hormone, has the potential to require less frequent injections than current growth disorder treatments. Eporal (erythropoietin) is an orally available version of the hormone that stimulates the body to produce more red blood cells and is used to treat anemia.

"We are looking forward to working with Nautilus Biotech," Sung-soo Jun, HanAll's executive vice president, said. "This collaboration reinforces HanAll Pharmaceutical's efforts to maintain and enhance its role as a leading player in the South Korean prescription drug market."